Etimumotide (CAS 1431550-68-3)

描述

1. Product Description 

Etimumotide (CAS 1431550-68-3) is a synthetic immunological agent designed for active immunization with significant potential as an antineoplastic research tool. It belongs to a class of experimental peptides that enhance host immune system recognition of tumor-associated antigens, enabling researchers to investigate new approaches to cancer immunotherapy and vaccine development.

Background

Cancer remains a leading cause of mortality worldwide, and immunotherapy is at the forefront of modern oncology research. Etimumotide represents a class of experimental peptides engineered to stimulate adaptive immune responses against tumor cells. Unlike passive therapies, Etimumotide encourages the immune system to generate long-lasting immunity, an essential attribute for vaccine-based cancer prevention or therapy.

Scientific Relevance

• Cancer Immunology: Investigating tumor-specific immune activation.

• Vaccine Development: Serving as a peptide backbone in experimental cancer vaccines.

• Oncology Research: Testing efficacy in tumor regression and immune checkpoint synergy.

• Preclinical Immunology Models: Evaluating antigen presentation, T-cell activation, and immune memory induction.

Research Value

Etimumotide provides unique opportunities for researchers:

• Exploration of tumor microenvironment interactions.

• Modeling immune checkpoint inhibitor synergy.

• Benchmarking against other experimental antineoplastic immunomodulators.

• Studying potential in translational oncology research.

2. Product Specifications 

3. Mechanism of Action & Research Applications 

Mechanism of Action

Etimumotide functions as a tumor-targeting immunological peptide with dual mechanisms:

1. Active Immunization

   • Stimulates antigen-presenting cells (APCs) to present tumor-related epitopes.

   • Activates T-helper and cytotoxic T-lymphocytes (CTLs).

   • Induces long-lasting immune memory against tumor-associated antigens.

2. Antineoplastic Activity

   • Enhances tumor cell recognition by immune effector cells.

   • Facilitates immune-mediated tumor regression.

   • Works synergistically with immune checkpoint inhibitors.

3. Immunomodulation

   • Reprograms the tumor microenvironment to favor immune activation.

   • Reduces immune suppression typically observed in tumors.

Research Applications

1. Oncology Research

   • Preclinical evaluation of Etimumotide in murine tumor regression models.

   • Benchmark studies in immune checkpoint blockade combinations.

2. Vaccine Development

   • Serving as a peptide platform in experimental cancer vaccine research.

   • Studies on antigen processing, MHC binding, and epitope presentation.

3. Immunology Studies

   • Exploration of T-cell mediated immune pathways.

   • Investigations into immune tolerance reversal.

4. Translational Research

   • Development of combination immunotherapies.

   • Synergy with monoclonal antibodies, adjuvants, and cytokine modulators.

5. Comparative Studies

   • Evaluation versus other tumor vaccine peptides.

   • Studying unique peptide structural features enabling immune activation.

     

4. Side Effects (Research Reference)

In research contexts, Etimumotide may show the following experimental effects:

• Local inflammation: Injection-site inflammation in animal models due to immune activation.

• Cytokine release: Dose-dependent cytokine induction can alter systemic immune responses.

• Immune overactivation: Risk of experimental autoimmune reactions in preclinical settings.

• Tumor lysis effects: Strong immune responses may induce tumor lysis syndrome-like phenomena in research animals.

• Stability concerns: Requires proper storage to maintain immunological activity.

 These findings are restricted to laboratory settings. Etimumotide is not approved for human or veterinary use.

5. Disclaimer

For laboratory research use only. Not for human or veterinary use.

6.  Keywords

• Etimumotide

• Etimumotide CAS 1431550-68-3

• Immunological agent for active immunization

• Antineoplastic research peptide

• Cancer vaccine peptide research

• Tumor immunology peptide

• Experimental oncology peptide GMP

• GMP-grade immunotherapy peptide supplier

• Immunological cancer research agent

• Active immunization antineoplastic peptide